HDACi - Targets beyond chromatin

Cancer Letters

Volumn 280, Issue 2, 2009, Pages 160-167

  Buchwald, Marc ^a   Krämer, Oliver H ^a   Heinzel, Thorsten ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Acetylation; NF kappaB; Proteasomal degradation; Signaling crosstalk; STATs

Indexed keywords

ALPHA INTERFERON; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT PROTEIN; VALPROIC ACID;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PREVENTION; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; SHORT SURVEY; TUMOR GROWTH; UBIQUITINATION;

EID: 67349202438     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.028     Document Type: Review

References (87)

1. Lehrmann H., Pritchard L.L., and Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86 (2002) 41-65
2. Mai A., Massa S., Rotili D., Cerbara I., Valente S., Pezzi R., Simeoni S., and Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25 (2005) 261-309
3. Krämer O.H., Baus D., Knauer S.K., Stein S., Jager E., Stauber R.H., Grez M., Pfitzner E., and Heinzel T. Acetylation of stat1 modulates NF-kappaB activity. Genes develop. 20 (2006) 473-485
4. Krämer O.H., Göttlicher M., and Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12 (2001) 294-300
5. Melnick A., and Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9 (2002) 322-332
6. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
7. Carey N., and La Thangue N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. 6 (2006) 369-375
8. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
9. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
10. Yang X.J., and Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31 (2008) 449-461
11. Sangeetha S., Wagner T., Heinzel T., and Kramer O.H. Acetylation of non-histone proteins. Int. J. Biochem. Cell Biol. (2008)
12. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
13. Das C., and Kundu T.K. Transcriptional regulation by the acetylation of nonhistone proteins in humans - a new target for therapeutics. IUBMB Life 57 (2005) 137-149
14. Sakuma T., Uzawa K., Onda T., Shiiba M., Yokoe H., Shibahara T., and Tanzawa H. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol. 29 (2006) 117-124
15. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S., and Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 10 (2004) 6962-6968
16. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., and Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281 (2006) 13548-13558
17. Zhu P., Huber E., Kiefer F., and Göttlicher M. Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell cycle 3 (2004) 1240-1242
18. Heinzel T., and Krämer O.H. Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discov. Today 4 (2007) 277-283
19. Yoshida M., Shimazu T., and Matsuyama A. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog. Cell Cycle Res. 5 (2003) 269-278
20. Kim I.A., Shin J.H., Kim I.H., Kim J.H., Kim J.S., Wu H.G., Chie E.K., Ha S.W., Park C.I., and Kao G.D. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin. Cancer Res. 12 (2006) 940-949
21. Camphausen K., Cerna D., Scott T., Sproull M., Burgan W.E., Cerra M.A., Fine H., and Tofilon P.J. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114 (2005) 380-386
22. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo. J. 20 (2001) 6969-6978
23. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
24. Li A.G., Piluso L.G., Cai X., Gadd B.J., Ladurner A.G., and Liu X. An acetylation switch in p53 mediates holo-TFIID recruitment. Mol. Cell 28 (2007) 408-421
25. Tang Y., Zhao W., Chen Y., Zhao Y., and Gu W. Acetylation is indispensable for p53 activation. Cell 133 (2008) 612-626
26. Mujtaba S., He Y., Zeng L., Yan S., Plotnikova O., Sachchidanand, Sanchez R., Zeleznik-Le N.J., Ronai Z., and Zhou M.M. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell 13 (2004) 251-263
27. Chen L.F., and Greene W.C. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J. Mol. Med. 81 (2003) 549-557
28. Kiernan R., Bres V., Ng R.W., Coudart M.P., El Messaoudi S., Sardet C., Jin D.Y., Emiliani S., and Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278 (2003) 2758-2766
29. Ray S., Lee C., Hou T., Boldogh I., and Brasier A.R. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res. 36 (2008) 4510-4520
30. Tang X., Gao J.S., Guan Y.J., McLane K.E., Yuan Z.L., Ramratnam B., and Chin Y.E. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131 (2007) 93-105
31. Yuan Z.L., Guan Y.J., Chatterjee D., and Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307 (2005) 269-273
32. Nadiminty N., Lou W., Lee S.O., Lin X., Trump D.L., and Gao A.C. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc. Natl. Acad. Sci. USA 103 (2006) 7264-7269
33. Vervoorts J., Luscher-Firzlaff J.M., Rottmann S., Lilischkis R., Walsemann G., Dohmann K., Austen M., and Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 4 (2003) 484-490
34. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
35. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., and Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 (2005) 1768-1776
36. Bali P., George P., Cohen P., Tao J., Guo F., Sigua C., Vishvanath A., Scuto A., Annavarapu S., Fiskus W., Moscinski L., Atadja P., and Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 10 (2004) 4991-4997
37. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., and Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94 (2002) 504-513
38. Sun S.C., and Xiao G. Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metast. Rev. 22 (2003) 405-422
39. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
40. Calao M., Burny A., Quivy V., Dekoninck A., and Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem. Sci. 33 (2008) 339-349
41. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005) 375-386
42. Haura E.B., Turkson J., and Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2 (2005) 315-324
43. Hodge D.R., Hurt E.M., and Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41 (2005) 2502-2512
44. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
45. Bromberg J.F., and Darnell Jr. J.E. Potential roles of Stat1 and Stat3 in cellular transformation. Cold Spring Harb. Symp. Quant. Biol. 64 (1999) 425-428
46. Battle T.E., and Frank D.A. The role of STATs in apoptosis. Curr. Mol. Med. 2 (2002) 381-392
47. Kim H.S., and Lee M.S. STAT1 as a key modulator of cell death. Cell Signal 19 (2007) 454-465
48. Nusinzon I., and Horvath C.M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. USA 100 (2003) 14742-14747
49. Ray S., Boldogh I., and Brasier A.R. STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology 129 (2005) 1616-1632
50. Wang R., Cherukuri P., and Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 280 (2005) 11528-11534
51. O'Shea J.J., Kanno Y., Chen X., and Levy D.E. Cell signaling. Stat acetylation - a key facet of cytokine signaling?. Science 307 (2005) 217-218
52. Eickhoff B., Germeroth L., Stahl C., Kohler G., Ruller S., Schlaak M., and van der Bosch J. Trichostatin A-mediated regulation of gene expression and protein kinase activities: reprogramming tumor cells for ribotoxic stress-induced apoptosis. Biol. Chem. 381 (2000) 1127-1132
53. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., Mullen T.M., Glass C.K., and Rosenfeld M.G. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279 (1998) 703-707
54. Klampfer L., Huang J., Swaby L.A., and Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279 (2004) 30358-30368
55. Klampfer L., Huang J., Sasazuki T., Shirasawa S., and Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 1 (2003) 855-862
56. Krämer O.H., Knauer S.K., Greiner G., Jandt E., Reichardt S., Gührs K.H., Stauber R.H., Böhmer F., and Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Develop. 23 (2009) 223-235
57. Paulson M., Press C., Smith E., Tanese N., and Levy D.E. IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat. Cell Biol. 4 (2002) 140-147
58. Wang Y., Cui H., Schroering A., Ding J.L., Lane W.S., McGill G., Fisher D.E., and Ding H.F. NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat. Cell Biol. 4 (2002) 888-893
59. Shen H., and Lentsch A.B. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am. J. Physiol. Cell Physiol. 286 (2004) C840-847
60. Sizemore N., Agarwal A., Das K., Lerner N., Sulak M., Rani S., Ransohoff R., Shultz D., and Stark G.R. Inhibitor of kappaB kinase is required to activate a subset of interferon gamma-stimulated genes. Proc. Natl. Acad. Sci. USA 101 (2004) 7994-7998
61. Wang Y., Wu T.R., Cai S., Welte T., and Chin Y.E. Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol. Cell Biol. 20 (2000) 4505-4512
62. Suk K., Chang I., Kim Y.H., Kim S., Kim J.Y., Kim H., and Lee M.S. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J. Biol. Chem. 276 (2001) 13153-13159
63. Krämer O.H., Knauer S.K., Zimmermann D., Stauber R.H., and Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27 (2008) 732-740
64. Hayashi T., Ishida Y., Kimura A., Iwakura Y., Mukaida N., and Kondo T. IFN-gamma protects cerulein-induced acute pancreatitis by repressing NF-kappa B activation. J. Immunol. 178 (2007) 7385-7394
65. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
66. Ganster R.W., Guo Z., Shao L., and Geller D.A. Differential effects of TNF-alpha and IFN-gamma on gene transcription mediated by NF-kappaB-Stat1 interactions. J. Interferon Cytokine Res. 25 (2005) 707-719
67. Mukhopadhyay A., Shishodia S., Fu X.Y., and Aggarwal B.B. Lack of requirement of STAT1 for activation of nuclear factor-kappaB, c-Jun NH2-terminal protein kinase, and apoptosis by tumor necrosis factor-alpha. J. Cell Biochem. 84 (2002) 803-815
68. Hiroi M., and Ohmori Y. The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-kappa B for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-gamma gene. J. Biol. Chem. 278 (2003) 651-660
69. Blanchard F., and Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov. Today 10 (2005) 197-204
70. Krämer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., and Göttlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. Embo J. 22 (2003) 3411-3420
71. Krämer O.H., Müller S., Buchwald M., Reichardt S., and Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. Faseb J. 22 (2008) 1369-1379
72. Makki M.S., Heinzel T., and Englert C. TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic Acids Res. 36 (2008) 4067-4078
73. Alao J.P., Lam E.W., Ali S., Buluwela L., Bordogna W., Lockey P., Varshochi R., Stavropoulou A.V., Coombes R.C., and Vigushin D.M. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin. Cancer Res. 10 (2004) 8094-8104
74. Peterson L.F., and Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 23 (2004) 4255-4262
75. Slack J.L., and Rusiniak M.E. Current issues in the management of acute promyelocytic leukemia. Ann. Hematol. 79 (2000) 227-238
76. Fanelli M., Fantozzi A., De Luca P., Caprodossi S., Matsuzawa S., Lazar M.A., Pelicci P.G., and Minucci S. The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J. Biol. Chem. 279 (2004) 5374-5379
77. Yang G., Thompson M.A., Brandt S.J., and Hiebert S.W. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 26 (2007) 91-101
78. Park J.H., Jong H.S., Kim S.G., Jung Y., Lee K.W., Lee J.H., Kim D.K., Bang Y.J., and Kim T.Y. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J. Mol. Med. 86 (2008) 117-128
79. Zhou Q., Shaw P.G., and Davidson N.E. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res. Treat. (2008)
80. De los Santos M., Zambrano A., Sanchez-Pacheco A., and Aranda A. Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol. Endocrinol. 21 (2007) 2416-2426
81. Chen W.Y., Weng J.H., Huang C.C., and Chung B.C. Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). Mol. Cell Biol. 27 (2007) 7284-7290
82. Lan H.C., Li H.J., Lin G., Lai P.Y., and Chung B.C. Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and c-Jun phosphorylation. Mol. Cell Biol. 27 (2007) 2027-2036
83. Bashir T., Dorrello N.V., Amador V., Guardavaccaro D., and Pagano M. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428 (2004) 190-193
84. Carew J.S., Giles F.J., and Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269 (2008) 7-17
85. Pei X.Y., Dai Y., and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10 (2004) 3839-3852
86. Heider U., von Metzler I., Kaiser M., Rosche M., Sterz J., Rotzer S., Rademacher J., Jakob C., Fleissner C., Kuckelkorn U., Kloetzel P.M., and Sezer O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur. J. Haematol. 80 (2008) 133-142
87. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., and Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110 (2007) 267-277